r/TLRY

Hey guys, if you missed it, CytoDyn just settled $500K with investors over claims it misled the market about its drug leronlimab some time ago. And they have already sent the agreement to the court for final approval.

In a nutshell, in 2021, CytoDyn was accused of overstating the effectiveness and regulatory progress of leronlimab. In short, the FDA later said the company’s claims were not supported by data, revealing no clear benefit. 

After this news came out, the stock dropped 25%, and investors filed a lawsuit for their losses.

The good news is that the company recently agreed to settle $500K with them, and already sent this agreement to the court for final approval. So, if you invested in $CYDY when all of this happened, you can check the details and file your claim here.

Anyway, has anyone here invested in $CYDY at that time? How much were your losses, if so?

source: https://infolib.org/

LOGO UPGRADED

Friday May 15 I received the notice from Business of Cannabis my entry for Tilray was selected and on the Shortlist.

Monday May 18 I emailed the news to Tilray IR.

I'm happy to see they had the logo up graded to 'Tilray Medical' both photos attached.

BOFC Awards Shortlist | Tilray Brands

May 15, 2026

image

Hello Dave,

We're thrilled to let you know, that you have been shortlisted for the Business of Cannabis Awards 2026 —Huge congratulations!

🏆 Cannabis Team of the Year - Tilray Brands

From here, your entry moves into a second round of judging with our independent panel. Winners are announced on the night, 26 May, Rivington Street, London.

I've attached your BofC branded nominee asset. We have several logos on file for Tilray. If the logo in the asset below is incorrect, please let me know ASAP and I'll send you an amended asset.

🎟️ Tickets: businessofcannabis.com/awards

So excited to celebrate you on 26 May! Huge congrats again!

If NVIDIA fails to deliver a clear beat and a higher forward guidance tonight, I expect a significant capital rotation out of mega-cap tech. In that scenario, the Russell 2000, small caps, and higher-risk assets like cannabis stocks and cryptocurrencies could rally aggressively — similar to the rotation we saw in 2021.

That’s exactly the setup I’m hoping for 😎😁

The real question then becomes: which stocks could benefit the most from that move?

by NORML Posted on May 20, 2026

The US House of Representatives has approved legislation – the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act for Fiscal Year 2027 – which includes language allowing physicians associated with the Department of Veterans Affairs to officially recommend medical cannabis to military veterans in states where its use is legal.

The provision, introduced by Congressional Cannabis Caucus co-chairs Brian Mast (R-FL), Dina Titus (D-NV) and David Joyce (R-OH), addresses a long-standing barrier facing America’s veterans. Under current federal policy, Veterans Affairs doctors are legally prohibited from providing cannabis recommendations to their patients, even in states where medical marijuana is permitted. As a result, many veterans are forced to seek out private – often prohibitively costly – physicians in order to participate in these programs.

The House-approved language reflects growing bipartisan recognition that veterans should not be denied access to medical cannabis simply because they primarily receive healthcare through the VA system. Approximately one in ten military veterans report using cannabis, and nearly half say they do so for therapeutic purposes – such as to manage chronic pain and symptoms associated with post-traumatic stress.

Allowing VA physicians to recommend medical cannabis in accordance with state laws ensures that veterans can access regulated, lab-tested products through licensed providers instead of relying on the unregulated market. It also strengthens the relationship between veterans and their healthcare providers by allowing patients to discuss cannabis use openly and honestly within the VA system.

Most military veterans and their family members say that the Department of Veterans Affairs should provide medical cannabis treatment to eligible patients. Seventy-five percent of veterans say that they “would be interested in using cannabis or cannabinoid products as a treatment option if it were available.”

Last year, both chambers of Congress included similar provisions in their respective military funding bills. Nonetheless, the language was inexplicably left out of the consolidated bill

The FY27 bill now advances to the Senate, where lawmakers will decide whether to retain the provision in the final appropriations package.

https://norml.org/blog/2026/05/20/house-approved-funding-bill-provides-medical-cannabis-access-for-veterans/

BrewDog Japan

BREWDOG × SATANIC Collaboration Beer

"SATANIC BLOODY IPA" Now Available!

Exclusive sale at SATANIC CARNIVAL 2026 venue 📅 June 6 (Sat) · 7 (Sun) 📍 Makuhari Messe International Exhibition Hall

A punchy bitterness paired with the refreshing aroma of blood orange.

Crank up the heat in this blazing venue with just one glass.

May 20, 2026 businessofcannabis

Canadian producers shipped 17,067kg of medical cannabis directly to the UK in 2025, more than six times the 2,578kg recorded the year before, according to the latest official Home Office data seen by Business of Cannabis.

It comes as the total amount of cannabis flower being imported into the UK more than doubled in 2025 to 30,062kg, up from 14,992kg recorded in 2024, marking the highest annual figure in the market’s history.

Rather than pointing to a dramatic increase in Canadian cannabis imports, which have dominated European markets since the sector first emerged nearly a decade ago, this data points to a dramatic restructuring of supply chains.

As we reported in March 2025, up until last year, the UK had imported more medical cannabis from Spain than from any other country. While data on the origin country of this product is unavailable, it’s understood that the bulk of this cannabis came from Canada to be processed in Spain, Portugal and other European states before heading to the UK.

That dynamic is quickly shifting, as Canadian producers increasingly process their own products in domestic EU-GMP facilities and send flower in bulk directly, cutting out the middleman.

Prohibition Partners has analysed this data in granular detail and will be publishing a new report in the coming days, while presenting the data and analysis during Cannabis Europa London 2026.

Alex Khourdaji, Lead Analyst at Prohibition Partners, said: “The growth underscores the dominance of the Canadian medical cannabis supply, driven by excess production, tight domestic margins and Canadian licensed producers’ international expansion strategies.”

Reading the numbers The FOI figures, secured by Prohibition Partners and Business of Cannabis (dated 10 April 2026), cover dried cannabis flower (flos) preparations classified as unlicensed specials. They do not include extract products, Active Pharmaceutical Ingredients, or any imports from the Crown Dependencies.

As previously noted, the data records the country from which a shipment was processed and exported to the UK, rather than necessarily the country where cannabis was originally cultivated. (graph attached)

The raw 2023 total (26,973kg) risks obscuring the underlying trend. According to the data, Finland supplied 20,113kg across the first two quarters of 2023 alone, in two near-identical batches of approximately 10,056kg each, before disappearing entirely from the data; no imports from Finland appear in either 2024 or 2025.

Prohibition Partners has previously noted that Finland does not export medical cannabis and excluded those volumes from its own analysis. Setting those shipments aside, the adjusted 2023 baseline falls to approximately 6,860kg, consistent with a market that has roughly doubled in volume for two consecutive years.

On a quarterly basis, the acceleration within 2025 is even more pronounced. Imports rose from 5,285kg in Q1 to 11,810kg in Q4, a 123% increase across the year, with direct Canadian shipments accounting for 7,839kg of that final quarter figure alone.

Khourdaji suggested that this pattern pointed to a structural shift in how the market was being supplied: “The data suggests a move from incremental, clinic-led growth to larger, wholesale-driven procurement cycles and stronger inventory build-ups towards the end of the year.”

The Home Office notes that 2025 data remains provisional and may be subject to adjustment upon completion of the INCB Annual Returns process, which concludes 30 June 2026.

A shifting supply chain The growth in direct Canadian shipments has coincided with a decline in volumes from Spain and Germany, countries whose imports have historically included Canadian-origin product processed and packaged before export to the UK.

Spain shipped 3,517kg in 2023 and remained the leading processing hub through early 2025. When Business of Cannabis last reported on UK import data in March 2025, Spain had already shipped close to a tonne in Q1 of that year. (graph attached)

Spain’s quarterly volumes fell from 1,591kg in Q1 2025 to 1,176kg in Q2, 490kg in Q3, and 161kg in Q4, as direct Canadian shipments expanded rapidly in the second half of the year. Spain’s full-year 2025 total of 3,417kg represented 11.4% of total imports.

Germany supplied 1,014kg in 2023 and 1,963kg in 2024, but fell back to 1,404kg in 2025.

Portugal moved in the opposite direction, growing from 384kg in 2023 to 2,466kg in 2024 and 3,971kg in 2025. South Africa recorded the most consistent growth of any supplier outside Canada and Portugal, rising from 42kg in 2023 to 421kg in 2024 and 1,345kg in 2025. (graph attached)

Three countries shipped dried medical cannabis flower to the UK for the first time in 2025. Switzerland supplied 354kg across the year, the Czech Republic 142kg, and Greece 105kg. Israel, which had supplied trace quantities in both prior years, grew to 186kg.

The 14 source countries recorded in 2025, up from 11 in 2024, reflect the continued maturation of international supply chains into the UK market.

What comes next The Q4 2025 run rate, if sustained, implies annual imports of approximately 47,000kg in 2026. Whether that trajectory holds will depend on whether the large, wholesale-scale procurement patterns visible in H2 2025 continue, or whether Q4 represented inventory build-up ahead of anticipated demand.

Prohibition Partners’ UK Medical Cannabis Market Update 2026 examines what the import figures mean for market structure, competitive dynamics, and the supply chain outlook through 2030, including a full analysis of re-export channels and Canada’s estimated true share of UK supply.

https://businessofcannabis.com/uk-medical-cannabis-imports-hit-30-tonnes-as-canadian-producers-bypass-european-processors/

Not saying this is the reason a director would sell. It’s not so much a red flag like being discussed here is what I’m trying to say. Obviously, investors prefer to see directors holding a large percentage of shares to better align decision making with shareholder’s. It could also be a form of independence should tough decisions need to be made. Just putting that out there!

https://www.tsa.gov/travel/security-screening/whatcanibring/items/medical-marijuana

The Department of Justice’s progression toward federal Schedule III rescheduling is structurally fundamentally transforming the cannabis sector. By eliminating the punitive Section 280E tax burden, profitable U.S. operators are unlocking massive institutional-grade cash flow.

While some Canadian LPs like Tilray & Canopy entered USA building foundations outside of Sch 1 cannabis, other Cdn Lps face a prolonged timeline to enter the U.S. market—as noted by the Organigram (OGI) leadership team, suggesting in a May 4 interview 2-5 more years waiting for firm regulations.

BUT forward-looking capital is already rotating into dominant Multi-State Operators (MSOs) and clinical-stage biotechnology. (Simon has recently mentioned they would consider a Pharma partner once Sch3 in place).

For investors trapped in retail echo chambers (e.g., Stockhouse, X) blaming management for macroeconomic headwinds, it is time to reassess your thesis and reallocate capital to where structural alpha resides. Sell your Tilray and move to these stronger USA plays. I think of this song often hearing you every day: https://www.youtube.com/watch?v=lEM5x3Uf0lY

1. Core Structural Plays:

Top U.S. Operators & Diversified Vehicles. SWAP OUT

• Curaleaf Holdings (CURLF / CURA): The dominant global footprint strategy. It is uniquely positioned to capture massive market share across both transitioning U.S. states and early-stage European medical/adult-use markets (specifically Germany and the UK. Bought 2 very small EU-GMP facilities in Portugal & Canada to test the EU markets, would need major expansions to grow and expand).

• Green Thumb Industries (GTBIF / GTII): The premier financial discipline pick. Green Thumb consistently leads the tier-one USA peers in GAAP profitability and cash flow generation, backed by an active, shareholder-friendly stock buyback program. (I've held GTII on and off since 2020)

• Trulieve Cannabis (TCNNF): The lean, efficiency model. Its optimized seed-to-sale infrastructure in cornerstone states has significantly de-risked its balance sheet after successfully retiring $368 million in debt.

• Advisor Shares Pure US Cannabis ETF (MSOS): All-in-one vehicle for diversified exposure to U.S. operators via total return swaps, mitigating single-stock operational risks. (great option for those hating single CEOs, many CEOs here)

2. Filter Out Retail Noise: (use the BLOCK button)

• Social media scapegoating (e.g., following the recent public fallout surrounding high-profile CEO interview cancellations) destroys objective analysis. (I've heard from people Irwin should never accepted their original PODCAST invites, then they turned on him, putting out hit pieces).

• Block the toxic sentiment loops; focus entirely on balance sheets and regulatory macro-flows. (I expect good YoY improves with Yearend 2026 when released in July).

3. The Bio-Pharma Disruption Frontier

The next secular growth wave in cannabinoids belongs to strictly regulated, clinical-stage biotechnology rather than consumer packaged goods.

Vertanical (VER-01): Just Today, a German clinical-stage biopharma company disrupting traditional pain management, by securing FDA Breakthrough Therapy Designation for its cannabis-derived, non-opioid therapeutic, it directly targets a $3 billion addressable market for chronic back pain.

NOTE: This sector is where most Tilray investors believe Tilray Medical USA finds their sweet spot.

4. The Strategic USA Foundation

• Tilrays Beer Footprint for future expanded Infused Beverages:

Tilray acquired iconic craft brands like 10 Barrel, Atwater, BluePoint, Montauk, SweetWater, Breckenridge, etc making them a top-tier U.S. craft brewer. Rated #4 in the USA. Once BrewDog added this past month, the Brewers Association remarked Tilray Craft Beers likely move to #3 in the USA Craft Beer passing Sierre Nevada in sales and volume. How will Tier 1 Beer addition of Carlsberg move Tilray USA?

• The Wellness Entry: Ownership of Manitoba Harvest provides Tilray with massive hemp-based distribution across major U.S. grocery chains. Already in 17,000 USA retail stores. How many of those Whole Foods, etc have attached pharmacies, many?

• The Immediate Benefit: These categories generate clean, reliable cash flow and bypass standard cannabis tax penalties (Section 280E).

• The "Final Addition"

Swap. The true genius of this strategy is scalability.

Tilray did not just buy beverage companies for the alcohol; they bought a turnkey distribution network. They have established relationships with major distributors, state-of-the-art bottling facilities, and prime shelf space in mainstream retail.

When federal U.S. cannabis regulations inevitably shift, Tilray does not need to build supply chains from scratch.

They can simply trigger a strategic product "swap"—introducing THC-infused beverages and wellness products straight into their existing, fully compliant U.S. distribution pipelines.

Cannabis becomes the near-term final addition to a house they have already built.

PS - Tilray still have some hidden gems in Canada, US & UK

Given some of the posts on this subreddit regarding Irwin Simon's history, I thought it worthwhile to dig a bit deeper into Hain Celestial.

WARNING: This is a longer post (for those who are critical of the length of my posts, stop reading now and move on).

NOTE: This does not paint an entirely positive picture of Mr. Simon. That being said, my conclusion is I would think he learned a valuable lesson about buying too many brands and the dangers of having too many SKUs, some self-competing.

Perhaps Tilray is his do over and a change to make things right?

Here we go:

CNBC - 22 Jun 2017

Hain Celestial founder and CEO Irwin Simon on Thursday sought to reassure weary investors even as a lengthy accounting probe cleared the company of wrongdoing but failed to help its battered stock price.

Weighing on the shares is a weak outlook provided by management. Nonetheless, the chief executive was upbeat on the company’s future and also saw a silver lining in Amazon’s planned purchase of Whole Foods.

“Now is the time to move on and build our business and take it to the next level,” Simon said in an interview Thursday on CNBC’s “Squawk Alley.”

The CEO said the company completed the accounting review and audit process and found there was “no material change” to previously reported financials. He called it “a great outcome.”

MY CONCLUSION: Some have indicated in previous posts that Irwin Simon is a crook. An accounting probe on Hain Celestial actually cleared the company of wrong doing, BUT, the damage was done and stock price suffered. Amazon or Whole Foods never did buy Hain Celestial. Nestle was in talks, but felt there were too many brands.

New York Post - 4 Jan 2018

The Hain Celestial Group cannot find a buyer for the $4.2 billion market-cap company — despite being informally for sale for roughly a year, four sources familiar with the situation told The Post.

Founder and Chief Executive Irwin Simon built his New York organic-foods powerhouse to ultimately sell it, sources said, but failed to find a buyer because he expanded the company to include too many brands, the sources said.

No one brand is large enough to entice a suitor to pay Simon’s asking price, sources said.

Simon on Thursday declined to say whether Hain has been informally for sale but conceded that a public company like his is always available at the right price.

Hain, best-known for brands like Celestial Seasonings teas, Terra chips, Garden of Eatin’, Rudi’s and Earth’s Best, also has a stable full of lesser-known brands that represent a significant number of sales.

MY CONCLUSION: Irwin Simon acquired too many brands under Hain Celestial. This is something I am keeping an eye on with Tilray. I sincerely hope he learned his lesson at Hain Celestial and will find the right balance between expansion versus over-expansion. It would be nice if someone were to ask that question at the next Q-Call.

It's time for Irwin Simon to indicate how it will be "different" this time and not making the same error of over extension.

25 Jun 2018 - CNBC

Hain Celestial announced Monday that Irwin Simon is stepping down as CEO, a quarter of a century after he founded the organic food company.

Hain is working with an executive search firm to fill the post, and when a candidate is selected Simon will move on and become non-executive chairman.

The announcement comes as the owner of Terra Chips and Earth’s Best baby food is under pressure from activist investor investor Engaged Capital, which previously disclosed a 9.9 percent stake. A settlement with the firm in October put Engaged’s founder, Glenn Welling, on the Hain board.

Shares of Hain closed up 0.5 percent Monday, giving it a market capitalization of $3.23 billion. Year to date, shares of the company have fallen roughly 29 percent. It had a 52-week high this past July of $45.61; today it trades at $29.89.

It is likely to once again raise speculation about a potential acquisition of the company. Rumors and potential suitors have swarmed Hain for years, but the company owns a number of different businesses — from tea to meat — making it a hard match for a single suitor.

Simon, meantime, is viewed as having the keys to the company’s complexities, as the singular person to have overseen its many deals. That knowledge stronghold had made potential buyers cautious, sources have told CNBC.

Hain has sought to streamline its businesses and is currently in the process of selling its protein unit. Still, the sale of the unit, which includes Plainville Farms poultry and FreeBird Chicken, faces challenges. Like the rest of Hain, the brand can no longer rest on the fact that it is organic as its stand-alone draw to shoppers. The organic food industry has become more crowded in recent years, thereby also making it more competitive.

Meantime, Simon’s departure adds one more to the ever-growing number of food company CEOs who have left their roles in the last few years, as pressures on the food industry continue to squeeze the country’s largest food companies. Simon had been the second-largest tenured packaged food company CEO, a position now held by Conagra Brands CEO Sean Connolly, who joined the company in 2015.

MY CONCLUSION: Like Hain Celestial, Tilray is acquiring a lot of businesses. I am also beginning to wonder if Mr. Simon is in the process of trying to sell Tilray (like he tried to do with Hain Celestial); or will history repeat itself and an organization like Engaged Capital try to buy 9.9% of Tilray and oust Simon and Merton? I am keeping an eye on volume of shares being traded. I would tend to think if someone was acquiring shares the share price would actually be going up. Perhaps Irwin Simon is waiting for S3 hearings this summer. If those hearings go well maybe Tilray would get acquired by a Constellation or Diageo? Will Simon seek to sell the company? He was trying to get 4B for Hain Celestial...I would let my shares go for 4X Friday's close!! Note: That was sarcasm, there is no comparison between Hain Celestial's market cap and Tilray's.

11 Nov 2025 - The Food Institute

In 1992, Irwin Simon, a veteran of Haagen-Dazs and Slimfast, set out on his own. As he recounted in a 2020 interview, he bought four separate businesses in the health food category, merged them, and took the new company public in a tiny offering. By mid-2015, Hain stock had returned well over 4,000%, and Hain had become one of the biggest players in organic and natural food. Its portfolio of brands including Celestial Seasonings, Garden of Eatin’, and gluten-free manufacturer Rudi’s — among many, many, others — drove $2.7 billion in revenue in fiscal 2015.

The seven-plus years since Simon’s departure, however, have been brutal.

Hain stock has collapsed; incredibly, shares are now in the red across their 33-year history. In 2016, an accounting issue scared off investors and eventually led to a rebuke from the Securities and Exchange Commission. Simon departed in 2018 and would soon enter the cannabis industry; according to multiple reports he had tried, and failed, to sell Hain in the years prior. Three successive CEOs have tried, and mostly failed, to stem the decline in Hain’s profits and stock price.

Simon’s acquisitive strategy — Hain incredibly bought 55 businesses across 25 years — worked at first, when Hain largely had the better-for-you category to itself. But as former CEO Mark Schiller noted at a 2018 Investor Day, new entrants arrived, and the management teams in place following Simon’s departure simply weren’t efficient enough to compete.

MY CONCLUSION: Hain Celestial did not work out well in the end. I am banking on Irwin Simon having learned a few things about striking the right balance between acquiring companies to take advantage of synergies and acquiring too many companies thus creating a situation where you go into competition with yourself. I cannot help but conclude Mr. Simon is setting Tilray up for a sale; if so, it is imperative he not put Tilray into a situation where there are too many companies under its umbrella.

I hope someone queries this at the next Q-call.

FINALLY: My next task will be to dive into how many companies/brands Tilray has acquired since Irwin Simon became CEO. I suspect it is around 15 or so. Let's hope it is nowhere near the 50 brands he acquired while at the helm of Hain Celestial. That was clearly a mistake.